Various mechanisms of action have been proposed for scleroderma, particularly the role of innate and adaptive immune systems in upregulating profibrotic and proinflammatory cytokines, such as transforming growth factor beta (TGF-β) and interleukin-6 (IL-6), respectively [2]. The gene discussed is IL6; the disease is scleroderma.